Adult Growth Hormone Deficiency: from Transition to Senescence
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Adult Growth Hormone Deficiency : from Transition to Senescence. / Jørgensen, Jens Ol; Hermansen, Kasper; Stochholm, Kirstine; Juul, Anders.
I: Pediatric Endocrinology Reviews, Bind 16, Nr. Suppl 1, 2018, s. 70-79.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Adult Growth Hormone Deficiency
T2 - from Transition to Senescence
AU - Jørgensen, Jens Ol
AU - Hermansen, Kasper
AU - Stochholm, Kirstine
AU - Juul, Anders
N1 - Copyright© of YS Medical Media ltd.
PY - 2018
Y1 - 2018
N2 - The acute metabolic actions of hGH were discovered in GH-deficient adults (GHDA) 60 years ago and placebo controlled trials of prolonged rhGH replacement therapy appeared 30 years after. Untreated GHDA causes excess morbidity and mortality from cardiovascular disease and the clinical features include fatigue, reduced aerobic exercise capacity, abdominal obesity, reduced lean body mass, osteopenia, and elevated levels of circulating cardiovascular risk biomarkers. Several of these abnormalities normalize with GH replacement. Frequent side effects are fluid retention and insulin resistance, which are reversible and dose-dependent. The dose requirement declines with age and is higher in women. Continuation of GH replacement into adulthood is indicated in some patients with childhood-onset disease so the diagnosis must be reassessed. Observational data show that mortality in GH replaced patients is reduced compared to untreated patients. Thus, GH replacement in GHDA has proven beneficial and safe.
AB - The acute metabolic actions of hGH were discovered in GH-deficient adults (GHDA) 60 years ago and placebo controlled trials of prolonged rhGH replacement therapy appeared 30 years after. Untreated GHDA causes excess morbidity and mortality from cardiovascular disease and the clinical features include fatigue, reduced aerobic exercise capacity, abdominal obesity, reduced lean body mass, osteopenia, and elevated levels of circulating cardiovascular risk biomarkers. Several of these abnormalities normalize with GH replacement. Frequent side effects are fluid retention and insulin resistance, which are reversible and dose-dependent. The dose requirement declines with age and is higher in women. Continuation of GH replacement into adulthood is indicated in some patients with childhood-onset disease so the diagnosis must be reassessed. Observational data show that mortality in GH replaced patients is reduced compared to untreated patients. Thus, GH replacement in GHDA has proven beneficial and safe.
U2 - 10.17458/per.vol16.2018.jhs.adultghdeficiency
DO - 10.17458/per.vol16.2018.jhs.adultghdeficiency
M3 - Journal article
C2 - 30378784
VL - 16
SP - 70
EP - 79
JO - Pediatric Endocrinology Reviews
JF - Pediatric Endocrinology Reviews
SN - 1565-4753
IS - Suppl 1
ER -
ID: 216565266